UP!

News

ANI Pharmaceuticals, Inc. -0.21% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-01 Future report Set alerts
Q3 2020 2020-11-09 Future report Set alerts
Q2 2020 2020-08-06 0.69 -1.03
Q1 2020 2020-05-07 1.04 -0.59
Q4 2019 2020-02-27 1.08 -0.41
Q3 2019 2019-11-06 1.23 0.32
Q2 2019 2019-08-07 1.44 0.53
Q1 2019 2019-05-09 1.30 0.04
Q4 2018 2019-02-27 1.32 0.46
Q3 2018 2018-11-06 1.29 0.42

Ratings

2016-07-10 Downgrade Oppenheimer Holdings Inc. Outperform
2016-07-08 Downgrade Citigroup Inc. Outperform to Market Perform $49.00
2016-06-22 Initiated Coverage Raymond James Strong-Buy $68.00
2016-06-22 Initiated Coverage Raymond James Financial Inc. Strong-Buy $68.00
2016-06-17 Reiterated Rating Guggenheim Buy $55.00 to $65.00
2016-05-24 Downgrade Standpoint Research Buy to Hold
2016-05-07 Reiterated Rating Guggenheim Buy $50.00 to $55.00
2016-05-03 Reiterated Rating Oppenheimer Buy
2016-05-03 Reiterated Rating Oppenheimer Holdings Inc. Buy
2016-04-13 Reiterated Rating Oppenheimer Buy $47.00 to $49.00
2015-11-13 Initiated Coverage Standpoint Research Buy $54.00
2015-11-04 Reiterated Rating Roth Capital Buy $60.00 to $56.00
2015-11-04 Lower Price Target Oppenheimer $55.00 to $50.00
2015-10-09 Lower Price Target Oppenheimer Outperform $65.00 to $55.00
2015-09-28 Upgrade Roth Capital Neutral to Buy $67.00 to $60.00
2015-08-04 Lower Price Target Roth Capital Neutral $70.00 to $67.00
2015-08-02 Reiterated Rating Oppenheimer Buy
2015-07-31 Boost Price Target Oppenheimer Outperform $72.00 to $74.00
2015-07-15 Boost Price Target Roth Capital Neutral $60.00 to $70.00
2015-06-23 Boost Price Target Oppenheimer Outperform $61.00 to $67.00
2015-05-18 Set Price Target Roth Capital Hold $78.00 to $60.00
2015-05-06 Lower Price Target Oppenheimer Outperform $69.00 to $61.00
2015-04-10 Downgrade Roth Capital Buy to Neutral $78.00
2015-03-06 Set Price Target Guggenheim Buy $79.00
2015-02-27 Set Price Target Roth Capital Buy $65.00 to $78.00
2015-02-26 Set Price Target Roth Capital Buy $78.00
2015-02-19 Set Price Target Roth Capital Buy $65.00 to $78.00
2015-02-19 Set Price Target Guggenheim Buy $79.00
2015-02-18 Boost Price Target Oppenheimer Outperform $58.00 to $69.00
2014-12-15 Initiated Coverage Guggenheim Buy $65.00
2014-11-20 Reiterated ROTH Capital Buy $55 to $65
2014-11-20 Boost Price Target Roth Capital Buy $55.00 to $65.00
2014-08-05 Boost Price Target Oppenheimer $35.00 to $37.00
2014-07-31 Reiterated Rating Oppenheimer Outperform $40.00 to $35.00
2014-05-06 Boost Price Target Roth Capital $36.00 to $38.00
2014-03-06 Boost Price Target Oppenheimer Outperform $31.00 to $40.00
2014-02-20 Boost Price Target Roth Capital $27.00 to $33.00
2014-02-19 Boost Price Target Oppenheimer Outperform $29.00 to $31.00
2014-01-22 Initiated Coverage Oppenheimer Outperform $29.00
2014-01-07 Initiated Coverage Roth Capital Buy $27.00
2016-07-10 Downgrade Oppenheimer Holdings Inc. Outperform
2016-07-08 Downgrade Citigroup Inc. Outperform to Market Perform $49.00
2016-06-22 Initiated Coverage Raymond James Strong-Buy $68.00
2016-06-22 Initiated Coverage Raymond James Financial Inc. Strong-Buy $68.00
2016-06-17 Reiterated Rating Guggenheim Buy $55.00 to $65.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
MERIDIAN VENTURE PARTNERS II LP 21636.22%  (2350559) ANIP /
MARSHBANKS TRACY 4147.65%  (450601) ANIP /
RAYNOR DANIEL 2660.19%  (289003) ANIP /
PRZYBYL ARTHUR President and CEO 1920.39%  (208631) ANIP /
Marken James G. Vice President, Operations 638.19%  (69333) ANIP /
Arnold Charlotte C. Chief Financial Officer 499.80%  (54298) ANIP /
Jamnick Robert J. VP, Quality & Product Develop. 442.91%  (48118) ANIP /
MANGANO ROSS J 247.74%  (26914) ANIP /
Schrepfer Robert W VP Bus Dev & Con Mfg 181.83%  (19754) ANIP /
Brown Robert E. JR 152.50%  (16568) ANIP /
HOLUBOW FRED 136.33%  (14811) ANIP /
CAREY STEPHEN P. Vice President and CFO 129.95%  (14118) ANIP /
Penn Thomas A. 102.26%  (11110) ANIP /
LANKAU PETER A 23.01%  (2500) ANIP /

Comments